Connect with us

Top Stories

Britain says 6,000 more people needed for trial of Merck COVID pill

Britain says 6,000 more people needed for trial of Merck COVID pill 1

LONDON (Reuters) – Britain said on Tuesday it needed to recruit 6,000 more people onto a trial of Merck’s COVID-19 antiviral pill molnupiravir to inform how the drug can be rolled out more widely.

Britain’s MHRA medicine regulator approved the pill, made by Merck and Ridgeback Therapeutics, in November, and the government launched a national study to establish the best way to use the drug.

The health ministry said that while 4,500 trial participants had signed up, thousands more were needed to gather the data needed.

The study, called Panoramic, was launched to assess how the antiviral should be used in a largely vaccinated population, given it was assessed in clinical trials on unvaccinated people.

“Antivirals are a hugely important addition to our response to COVID-19,” said Eddie Gray, chair of the UK’s Antivirals Taskforce.

“Getting people enrolled onto this study is vital, not just in protecting the most vulnerable now, but in ensuring we can deploy these medicines more widely as soon as possible.”

Prime Minister Boris Johnson last week said he would ditch mask mandates, work from home guidance and compulsory COVID passes in England, citing Britain’s purchase of antivirals as well as the booster rollout and the lower severity of the Omicron coronavirus variant.

The health ministry said it had bought 2.23 million courses of the Merck drug, as well as 2.75 million courses of an antiviral pill developed by Pfizer Inc which it has not yet started to deploy.

Merck’s pill was shown to reduce hospitalisations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.

The government said that over-50s and those with an underlying medical condition who had tested positive for COVID-19 on a PCR test or who were unwell with COVID symptoms in the last five days could sign up for the Panoramic study.

(Reporting by Alistair Smout; Editing by Mark Potter)

Editorial & Advertiser disclosure
Our website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Advertisement

Newsletters with Secrets & Analysis. Subscribe Now